(Alliance News) - Sensyne Health PLC on Thursday said it has joined Bayer AG's LifeHub UK, extending the artificial intelligence-focused collaboration between the two firms.
Shares in Sensyne were up 3.3% at 108.50 pence in London in morning trade.
Sensyne will partner with Bayer on its LifeHub UK projects, including "the development of AI-enabled radiology to enhance patient outcomes".
This inaugural AI project will analyse research from 3 million NHS patient records and imaging data from Sensyne's NHS trust partnerships so as to create a digital product for radiologists that can improve diagnosis and raise efficiency.
The NHS will remain as the controller of patient data, none of which will be sold or transferred to a third party.
LifeHub UK launches immediately and is intended to help with disease detection and drug discovery using "AI-enabled imaging solutions". It is part of Bayer's innovation hub network.
Bayer and Sensyne will embark on more joint research & development activities in the future around AI-enabled imaging.
Sensyne Chief Executive Paul Drayson said: "Initiatives like this are essential to quickly maximise the opportunity AI presents to improve patient care and accelerate medical research. I'm delighted to be working with Bayer, extending our partnership to deliver the benefits of digital innovation directly to clinicians and patients."
By Anna Farley; annafarley@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
